Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920110 · ClinicalTrials.gov registry record
Development of the ORCA Communication Measure for Rett Syndrome
A clinical trial, sponsored by Rett Syndrome Research Trust.
- Completed
- Registry status
- 272
- Enrollment target
NCT04920110: Completed study, sponsored by Rett Syndrome Research Trust.
NCT04920110 is a clinical trial that has completed, run by Rett Syndrome Research Trust. The registered enrollment target is 272 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04920110 has completed, sponsored by Rett Syndrome Research Trust.
- COMPLETED
- Registry status
- 272 participants
- Enrollment target
Study Summary
This measurement validation study will use qualitative and quantitative methodology to evaluate the Observer-Reported Communication Ability Measure (ORCA), to appropriately capture communication abilities in individuals with Rett syndrome. The ORCA Measure is a caregiver-reported questionnaire that collects caregiver observations of their child's communication abilities including expressive, receptive and pragmatic communication types. Caregivers will participate via phone interviews and online surveys. Approximately 270 participants will be enrolled.
Primary Outcome
Using qualitative and quantitative methodology the existing ORCA measure will be evaluated for use in Rett syndrome and modified if needed. The ORCA measure produces a single score that is an estimate of an individual's overall level of communication ability. Higher ORCA scores reflect greater communication ability; the mastery of expressive, receptive, and pragmatic types of communication and higher vocabularies for verbal words and symbols on assistive devices. The ORCA T-score range is from 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2022-02-10 |
What the finished NCT04920110 record still lists
NCT04920110 is an observational study that tracks outcomes without assigning an intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04920110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04920110 about?
NCT04920110 is a clinical study titled "Development of the ORCA Communication Measure for Rett Syndrome". This measurement validation study will use qualitative and quantitative methodology to evaluate the Observer-Reported Communication Ability Measure (ORCA), to appropriately capture communication abilities in individuals with Rett syndrome. The ORCA Measure is a caregiver-reported questionnaire that ...
What is the current status of trial NCT04920110?
This trial is currently completed. The enrollment target is 272 participants. The study started on 2021-07-02. Estimated completion is 2022-02-10.
Who is sponsoring clinical trial NCT04920110?
This trial is sponsored by Rett Syndrome Research Trust, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI